Jane Street Group LLC Decreases Stake in Organogenesis Holdings Inc. (NASDAQ:ORGO)

Jane Street Group LLC cut its holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO) by 50.4% during the third quarter, Holdings Channel reports. The institutional investor owned 46,866 shares of the company’s stock after selling 47,671 shares during the quarter. Jane Street Group LLC’s holdings in Organogenesis were worth $134,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of the business. Verition Fund Management LLC boosted its position in Organogenesis by 542.8% during the third quarter. Verition Fund Management LLC now owns 78,690 shares of the company’s stock worth $225,000 after purchasing an additional 66,448 shares in the last quarter. FMR LLC boosted its position in Organogenesis by 34.2% during the third quarter. FMR LLC now owns 173,595 shares of the company’s stock worth $496,000 after purchasing an additional 44,199 shares in the last quarter. AQR Capital Management LLC boosted its position in Organogenesis by 76.9% during the second quarter. AQR Capital Management LLC now owns 2,268,760 shares of the company’s stock worth $6,353,000 after purchasing an additional 986,132 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Organogenesis by 19.6% during the second quarter. Dimensional Fund Advisors LP now owns 2,036,743 shares of the company’s stock worth $5,702,000 after purchasing an additional 333,123 shares in the last quarter. Finally, State Street Corp boosted its position in Organogenesis by 0.6% during the third quarter. State Street Corp now owns 1,459,767 shares of the company’s stock worth $4,175,000 after purchasing an additional 9,090 shares in the last quarter. 49.57% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Organogenesis

In other news, CEO Gary S. Gillheeney sold 55,615 shares of the business’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $3.36, for a total value of $186,866.40. Following the completion of the transaction, the chief executive officer now directly owns 3,044,779 shares of the company’s stock, valued at $10,230,457.44. The trade was a 1.79 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders sold a total of 278,116 shares of company stock valued at $991,190 over the last three months. 36.90% of the stock is currently owned by insiders.

Organogenesis Stock Down 0.3 %

ORGO opened at $3.00 on Tuesday. The business’s fifty day moving average is $3.50 and its two-hundred day moving average is $3.08. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09. The company has a market cap of $377.18 million, a price-to-earnings ratio of -50.00 and a beta of 1.77. Organogenesis Holdings Inc. has a one year low of $2.16 and a one year high of $4.57.

Organogenesis (NASDAQ:ORGO) last posted its earnings results on Tuesday, November 12th. The company reported $0.09 EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.11. The company had revenue of $115.18 million for the quarter, compared to the consensus estimate of $109.59 million. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. During the same period in the previous year, the business earned $0.02 earnings per share. Analysts anticipate that Organogenesis Holdings Inc. will post -0.07 EPS for the current fiscal year.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.